Abiopharma

🔍 Cagney Michael Scott (Director)

Company: Figure Technology Solutions, Inc. (FIGR)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 67,840 shares of Class A Common Stock (Direct)
  Date: 2026-04-15 | Code: C | equity_swap_involved: 0 | shares_owned_after: 67,840.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 14,121 shares of Class A Common Stock at $33.8475 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 53,719.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 26,158 shares of Class A Common Stock at $35.1422 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 27,561.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 27,561 shares of Class A Common Stock at $35.9328 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F5
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-04-15 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 6,128,993.00
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-04-15 | Code: H | nature_of_ownership: By Family Trust | shares_owned_after: 17,661.00 | Footnotes: F6
• Sold 67,840 shares of Class B Common Stock (Derivative)
  Date: 2026-04-15 | Code: C | equity_swap_involved: 0 | shares_owned_after: 29,903,863.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Holds 4,313,645 shares of Class B Common Stock (Derivative)
  Date: 2026-04-15 | Code: H | shares_owned_after: 4,313,645.00 | Footnotes: F1, F1, F1
• Holds 2,237,012 shares of Class B Common Stock (Derivative)
  Date: 2026-04-15 | Code: H | shares_owned_after: 2,237,012.00 | Footnotes: F1, F1, F1
• Holds 3,185,970 shares of Class B Common Stock (Derivative)
  Date: 2026-04-15 | Code: H | shares_owned_after: 3,185,970.00 | Footnotes: F1, F1, F1
• Holds 3,185,970 shares of Class B Common Stock (Derivative)
  Date: 2026-04-15 | Code: H | shares_owned_after: 3,185,970.00 | Footnotes: F1, F1, F1

Footnotes:

• F1: Each outstanding share of Class B Common Stock will be convertible at any time at the option of the holder into one share of Class A Common Stock. In addition, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon any transfer, whether or not for value, except for certain permitted transfers.
• F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.56 to $34.395. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.595 to $35.58. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.605 to $36.35. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: Reflects shares acquired in a transaction exempt from reporting pursuant to Rule 16a-9.